Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Addiction Medicine Psychiatrists (US)

Articles with lock require a subscription to GLG News | Request a free trial
January 11, 2008
Cialis for Boy Scouts
Analysis of: Cialis Is Cleared for Daily Use | online.wsj.com
Author: GLG Expert Contributor
The notion that Lilly is promulgating here by marketing Cialis as a daily preparation is that you can have it both ways, namely always being prepared for sexual relations that are spontaneous.  From an observer of the human comedy (me), this will sell very well as the Baby Boom ages.  No mention...
January 8, 2008
If we view business interest as an indicator of efficacy glutamate-based treatment of schizophrenia is a success
Analysis of: Addex and Merck & Co., Inc. Enter License Agreement to Develop a Drug Candidate for Schizophrenia | www.pipelinereview.com:80
Author: GLG Expert Contributor
Allosteric modulation of the metabotropic glutamate receptor 5 (mGluR5) for treatment of schizophrenia seems highly promising from a basic science perspective.  It has not been well tested in the clinic yet.  The fact that two major pharmaceutical firms are now in the hunt towards clinical...
January 3, 2008
Serotonin and satiety is very interesting
Analysis of: Biovitrum has Successfully Completed the First Phase I Trial of its 5-HT6 Receptor Antagonist (BVT.74316) | www.pipelinereview.com
Author: GLG Expert Contributor
An interesting observation made as a consequence of the widespread use of serotonin specific reuptake inhibitors (SSRI) in clinical psychiatry is that these medications tend to affect appetite.  SSRIs can cause either weight gain or loss.  There was a time when they were extensively used in...
December 28, 2007
Would you be excited if I told you I had a new model car?
Analysis of: Lu AA21004 for the treatment of mood and anxiety disorders enters into clinical phase III | www.pipelinereview.com
Author: GLG Expert Contributor
Lu AA21004 is a new "bis-aryl-sulphanyl modulator" that has both preclinical and clinical support for future development for market as an "affective modulator". (I use the term affective modulator because I doubt whether the ultimate indication for this agent will be based on anxiety or depression.) ...
December 19, 2007
A new era in Parkinson's Disease treatment?
Analysis of: Arana Announces Phase II Trials For Lead Compound ART621 | www.peptech.com
Author: GLG Expert Contributor
Helping regenerate or preventing death of dopaminergic neurons in the motor system is novel and exciting.  That is the strategy described in the accomapanying clinical trial of insertion of a nerve growth factor gene into the putamen of patients with Parkinson’s disease—a region of the brain affected...
December 19, 2007
PRISTIQ--the new desipramine?
Analysis of: New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo | www.pipelinereview.com
Author: GLG Expert Contributor
Here we go again; look at all metabolites of a successful drug for efficacy to increase your bang for the corporate buck.  Brilliant--because success is virtually assured at relatively little cost.  Venlafaxine is a reasonably good antidepressant, and in my experience, useful except in...
December 19, 2007
A smart strategic move--how to maximize corporate benefit from a molecule
Analysis of: Forest Laboratories and Lundbeck announces positive results of Lexapro(R) phase III study in adolescents with major depression | www.pipelinereview.com
Author: GLG Expert Contributor
At this stage there is a paucity of antidepressants that are approved in adolescent depression, even though antidepressants were perhaps excessively used until the recent concern over their increasing suicide risk.  So it is a very good strategy to extend patent somewhat by cornering the adolescent...
November 26, 2007
Rimonabant for Weight Control: No Pain No Gain (or Loss)
Analysis of: Study Shows Weight-Loss Drug Rimonabant is Associated with Severe Adverse Psychiatric Events | pharmalive.com
Author: GLG Expert Contributor
We have been hoping that remonibant, the cannabinoid antagonist, would allow patients with obesity to lose weight "pharmacologically" without actually having to undergo the significant effort to reverse a lifetime of self-destructive behaviors that have culminated in pathological obesity--obesity that...
November 19, 2007
This may not be exactly what the doctor ordered
Analysis of: Abilify(R) (Aripiprazole) Supplemental New Drug Application For Bipolar I Disorder Pediatric Patients Accepted For Priority Review By FDA | www.medicalnewstoday.com
Author: GLG Expert Contributor
It is a good idea to have FDA approval for disorders in children because this aspect of the pharmacopea is not well developed.  Aripiprazole is an atypical "atypical" neuroleptic that will likely have some beneficial effects in behavioral dyscontrol, but is not likely specific to bipolar I disorder. ...
October 23, 2007
How do you differentiate between a good idea and revival of off-patent pharmaceuticals
Analysis of: OREXIGEN(TM) Therapeutics Initiates its Third Phase III Trial for Contrave(TM) to Treat Obesity | biz.yahoo.com
Author: GLG Expert Contributor
It is fundamentally a good idea to focus on central nervous system interventions for over-eating, as opposed to metabolic regulation of glucose catabolism in the periphery.  It is also very economical ("sound business") to use agents that are not patent-protected to try this really good idea. ...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 Next11 to 20 of 132

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747